Church of PeptidesSearch
Investigational · Not FDA-approved

Petrelintide

A different signal. The questions grow with the evidence.

Follow Subject One from molecular design and rat studies to early human trials, two phase 2 checkpoints and unanswered phase 3 questions.

Journey published October 20, 2026 · Evidence reviewed 2026-10-20

Start at the beginning →Where we are today
  1. 01The molecule that had to hold togetherLaboratory development · Paper published November 11, 2025
  2. 02A scale is not the whole animalDiet-induced obese rats · ADA poster, June 2024
  3. 03The first human-sized questionsCompleted phase 1 studies · Paper published April 22, 2026
  4. 04The benefits and the red flagsZUPREME-1 · Completed March 7, 2026 · Published September 29, 2026
  5. 05A different room, a different populationZUPREME-2 · Completed August 13, 2026 · Sponsor report October 7, 2026
  6. 06Three doors, no borrowed endingPhase 3 registry checkpoint · October 20, 2026
Today’s checkpoint

As of October 20, 2026: a published phase 2 obesity trial, sponsor-reported diabetes results, and three recruiting phase 3 studies. Development is not approval.

Open the medicine’s evidence profile · Other journeys

Documented milestones, not every unpublished experiment. The story is fictional; each chapter identifies the real study population and source.